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Dear Editor, 
I read with interest an article which revealed a 
preponderance of triple negative breast cancer 
[1](TNBC; 62.3%) in Uyo, Southern Nigeria.  Recent 
studies also documented high prevalence of TNBC 
in Northern Nigeria (46.6 to 52.6%) and Southern 
Nigeria (65 to 87%) when compared with other 
[2,3]countries.  Triple-negative breast cancer (TNBC) 
is an aggressive and invasive heterogeneous type of 
tumors that accounts for 15 to 20% of all female 
[1]breast cancers worldwide.  The tumours are 
negative for estrogen and progesterone receptors 
and lack human epidermal growth factor receptor 2 
amplification. Sung et al. stated that the risk of 
having TNBC varies with birthplace, especially 
[4]among black women.  The tumour is more 
frequently diagnosed in Nigerian women than 
[5,6]patients of European ancestry,  especially those 
.[1,2,7]below the age of 60 years  According to Zheng et 
al., Nigerian women with TNBC are 23.4 and 10.3 
times more likely to have BRCA1 and BRCA 2 
[7]mutations, respectively.  They also opined that 
BRCA mutations greatly influence invasiveness of 
TNBC than other gene mutations. This suggests that 
patients aged 60 years or less should be tested for the 
mutations. 
Few patients with TNBC respond to primary 
treatment options such as surgery, anthracycline- 
and taxane-based chemotherapy, and radiation 
therapy. This is because high rate of progression, 
reoccurrence, relapse and death in less than a year 
.[8]following treatment  Survival rate in high resource 
countries is greatly improved owing to fact that 
TNBCs are further subtyped to inform improved 
new molecular target therapies. Identifying patients 
with tumor-infiltrating lymphocytes (TILs; CD8+ 
TILs or a high CD8+/FOXP3+ ratio) and those 
expressing programmed death-ligand 1 (immune 
evasion molecules) in tumor microenvironment 
informs prognosis and molecular based therapeutic 
[5]targets.  Sadly, most Nigerian patients cannot afford 
the already subsidized fee for the hormonal-based 
subtyping, let alone paying for the current molecular 
technique for subtyping TNBCs. The different 
subtypes of TNBC include: 1. Basal-like subtype 
(BL 1 and 2); it accounts for 50 to 75% of all TNBC. 
Basal-like 1 is associated with an elevated DNA 
damage response, p53 and BRCA1 mutations, 
retinoblastoma gene inactivation, high Ki67 
expression, and downregulation of B cell, T cell and 
natural killer cells. 2. The luminal androgen receptor 
(LAR) subtype; it has 10 fold expression of androgen 
receptor than the other subtypes. 3. Mesenchymal 
and mesenchymal stem-like subtypes; possess high 
motility and cell differentiation while interfering 
with EGFR, calcium signaling, G-protein receptors. 
4. Immunomodulatory subtype; it is another type of 
basal-like subtype with high STAT genes and 
activated immune (TILs) cells. Specific therapies for 
basal-like subtype 1 (BL1), basal-like subtype 2 
(BL2), Immunomodulatory subtype (IM), 
Mesenchymal subtype (M), Mesenchymal stem cell-
like subtype (MSL) and Luminal subtype expressing 
androgen receptor (LAR) include cisplatin and poly-
AD-ribose polymerase (PARP) inhibitors, mToR 
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and Growth factor inhibitors, cisplatin and PARP 
inhibitors, NVP-BEZ235 (a PI3K/mTOR and 
growth Src factor inhibitor), dasatinib (an abl/src 
inhibitor), and bicalutamide (AR antagonist), 
[9]respectively.  Further molecular testing of all 
TNBCs will reduce wastage of time and resources, 
and improve the survival outcome of patients.
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